Sanofi Pasteur and MSD end European vaccines partnership
pharmafile | March 8, 2016 | News story | Medical Communications, Research and Development, Sales and Marketing |Â Â MSD, Sanofi Pasteur, Sanofi pasteur msd, vaccinesÂ
Sanofi Pasteur and MSD have announced that they will end their joint vaccines operations in Europe, bringing an end to a collaboration spanning three decades on the Sanofi Pasteur MSD joint venture.
The companies say they will instead integrate their respective European vaccine businesses into their operations, independently manage their product portfolios and pursue their own distinct growth strategies in Europe.
Sanofi Pasteur MSD, owned 50/50 by Sanofi Pasteur and MSD, was created in 1994 to develop and commercialise vaccines originating from both companies’ pipelines. At the time, it’s reached spanned European 19 countries, and the JV launched numerous vaccines originating from both companies pipelines, including for measles, meningitis and cervical cancer.
Sanofi Pasteur and MSD issued say in a joint statement: “We are proud of Sanofi Pasteur MSD’s successful 20-year history. Our joint venture has achieved considerable success over the past two decades from a public health and commercial perspective. After carefully considering our individual strategic priorities, alongside the economic and regulatory environments for vaccine operations in the European Union, we have mutually agreed that it is in our best interests to manage our vaccine product portfolios independently. We believe that focusing our efforts on opportunities unique to our respective companies will better position us to drive growth, execute in a more efficient manner and optimize vaccine coverage. By bringing vaccines more rapidly to market, both companies would deliver greater value to all stakeholders.”
The companies say they expect the project to be completed by the end of 2016, subject to local labour laws and regulations and regulatory approvals.
Joel Levy
Related Content
Valneva Scotland supports local cancer charity Team Jak FoundationÂ
Valneva Scotland, the country’s largest vaccine producer, has partnered with local West Lothian-headquartered charity, Team …
Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …
